Business Context and Reporting Period
This Form 8-K, dated November 8, 2012, reports on Abbott Laboratories (Abbott) and its wholly owned subsidiary, AbbVie Inc. (AbbVie). The filing details the creation of a direct financial obligation through the issuance of senior notes by AbbVie, which are guaranteed by Abbott. This transaction is part of the broader corporate restructuring involving the separation of Abbott's proprietary pharmaceutical business into AbbVie.
Key Financial Metrics and Debt Obligations
AbbVie issued a total of $14.7 billion in aggregate principal amount of senior notes. The specific tranches are as follows:
- Fixed 2015 Notes: $3.5 billion at 1.200% interest.
- 2017 Notes: $4.0 billion at 1.750% interest.
- 2018 Notes: $1.0 billion at 2.000% interest.
- 2022 Notes: $3.1 billion at 2.900% interest.
- 2042 Notes: $2.6 billion at 4.400% interest.
- Floating 2015 Notes: $0.5 billion (floating rate).
Abbott has guaranteed each series of Notes on an unsecured, unsubordinated basis. This guarantee is scheduled to terminate upon the distribution of AbbVie common stock to Abbott shareholders.
Material Changes and Transaction Structure
The Notes were issued via a private placement to qualified institutional buyers and non-U.S. persons. A specific portion of the 2022 Notes, totaling $3,037,486,000 (the "Exchanged Notes"), was issued to Abbott as partial consideration for the transfer of pharmaceutical assets. Abbott subsequently exchanged these Exchanged Notes with Morgan Stanley to satisfy and discharge previously issued commercial paper.
AbbVie intends to use the net proceeds from the sale of the Notes (excluding the Exchanged Notes) to make a cash distribution to Abbott, pay related fees, and fund general corporate purposes. Abbott plans to use these proceeds to fund previously announced cash tender offers for its own outstanding notes.
Guidance, Risks, and Covenants
Registration Rights and Interest Rate Penalties: AbbVie and Abbott agreed to file a registration statement to exchange the Notes for new registered notes. If this exchange offer is not completed by November 4, 2013, or if a "registration default" occurs, the annual interest rate on the Notes will increase by 0.25%. This penalty increases by an additional 0.25% for each subsequent 90-day period of default, up to a maximum additional rate of 1.00% per year.
Covenants: The Indenture restricts AbbVie and its subsidiaries from creating mortgages on principal domestic properties, entering into sale and leaseback transactions regarding such properties, and merging or consolidating with other entities without meeting specific conditions.
Events of Default: Default events include failure to pay interest for 30 days, failure to pay principal when due, breach of covenants for 90 days after notice, and specified bankruptcy or insolvency events.
Redemption: AbbVie may redeem most Note series at any time at a price equal to principal plus a make-whole premium. The Floating 2015 Notes cannot be redeemed prior to maturity.
Investor Verification Checklist
- Verify the total debt load of $14.7 billion and the specific maturity dates of each tranche.
- Confirm the status of the Abbott guarantee and the timeline for its termination upon the AbbVie spin-off.
- Monitor the deadline of November 4, 2013, for the completion of the exchange offer to avoid interest rate penalties.
- Review the use of proceeds to ensure alignment with the funding of Abbott's cash tender offers.
- Assess the impact of the new debt covenants on AbbVie's future capital structure flexibility.